The tariff refund finally banks — Cardinal's clean handoff to a 13–15% guide
Q4 EPS +40% (15 points from the telegraphed IEEPA recovery) caps a 37% year; FY27 guidance runs above the long-term algorithm even as GMPD's recovery carries an Iran-shaped asterisk.
CAH · Earnings Call · 2026-08-11
A quarter that banked the refund
Fiscal 2026 ended with the four-year execution story Hollar and Alt have been building, punctuated by the one-time tariff recovery first telegraphed on the prior call. In Q3, Jason Hollar was explicit that recognition was still conditional: “we have the potential for a $200 million refund based upon the tariffs that we paid up to the IEPA announcement... about half of that $200 million, we ultimately - if we receive it, we would expect to share in that about half range with our customers” — Jason Hollar, Chief Executive Officer · 2026-04-30. Nothing had been booked at that point. This quarter, it landed. CFO Aaron Alt: “we recorded a onetime $100 million net operating earnings benefit from IEEPA tariff refunds in our GMPD segment” — Aaron Alt, Chief Financial Officer · 2026-08-11. The tariff refund added $0.31 to EPS — roughly 15 of the 40 percentage points of growth. Cardinal is hardly alone: IEEPA refund surfaced in the global keyword trajectory this quarter, and a ring of reporters — GOLF, HLIO, KMB, MWA, ARHS — booked parallel benefits. This reads as a sector-wide clearing event rather than a Cardinal-specific windfall. The headline frame was unambiguous:Quarterly revenue reached $63.7B (+6%), taking the full-year number to $254B (+14%). Gross profit grew 16% for the quarter, and adjusted free cash flow hit $5B for the year — the foundation for the capital-return step-up discussed below.Strong demand, strong execution, strong profit, strong adjusted free cash flow, strong liquidity, targeted and increased investments in the business, incremental return of capital to shareholders. We did what we said we would do.
Pharma: strong, not outsized
Pharma remains the spine: $58.8B revenue (+6%) and $645M segment profit (+21%). The story is durable demand across brand, generics and Specialty — with BioPharma Solutions still on its glidepath to $1B by FY28, Theranostics growing ~30% and PET over 20%. The revenue line is churning with offsetting forces — GLP-1 tailwind and IRA WACC changes headwind, each worth roughly 500 bps — but profit is where the leverage shows. The most telling exchange came from Kevin Caliendo, who cheekily asked management to “quantify the difference between what is outsized demand and what is strong demand” — Kevin Caliendo, Analyst · 2026-08-11. Aaron sidestepped the formula — “we're not going to provide you with a mathematical formula on strong versus outsized” — Aaron Alt, Chief Financial Officer · 2026-08-11 — but Jason offered data points: Specialty at 25% growth this year slowing back to a mid-teens planning assumption, and generics volumes stepping down toward the 2–3% long-term range. Translation: FY27 assumes strong, not euphoric, demand. On regulatory flux, Hollar's confidence rests on the thesis he has pressed for two years — that regulatory change around drug pricing doesn't change the distributor's value. From the Q2 FY26 call, the counterpart point: “we remain the lowest paid component of the supply chain than anyone in the supply chain” — Jason Hollar, Chief Executive Officer · 2026-04-30. That pricing-power framing underpins the FY27 Pharma guide of 8–11% profit growth even with the 2027 IRA price changes hitting the revenue line.GMPD: the asterisk and the Iran watch
The one beat that deserved scrutiny: GMPD's reported profit of $150M, up $80M year over year, *includes* the $100M refund. Stripped of that, segment profit lands near $50M — a decline from the prior-year base. Management's guide is for roughly $50M of growth off the ex-IEEPA FY26 result, to $200–220M, and they were explicit about the swing factor — what Aaron flagged in the conflicts in Iran dependence of the commodity cost outlook. Jason was equally direct on commodities: “if these types of costs and rates stay elevated for the duration of our fiscal year, it's likely we'd be closer to that bottom end of our guidance range for GMPD” — Jason Hollar, Chief Executive Officer · 2026-08-11. Relative to the post-COVID inflation shock, he stressed the difference — surcharges and flexible agreements now blunt the diesel and resin pass-through — but the refund-free quarter shows the improvement plan still has ground to cover.FY27: above the algorithm, capital compounding
The guide is 13–15% EPS growth off a $10.95 baseline (excluding the $0.31 refund), or $12.40–$12.60 — above the reconfirmed 12–14% long-term algorithm. The tax rate holds at 19–20%, with Aaron noting “the 19% anticipated rate for '26 to be durable into '27” — Aaron Alt, Chief Financial Officer · 2026-08-11. Capital returns got a jolt: a $5B increase to repurchase authority (to $6.4B), at least $1B of buybacks planned for FY27, and a new $4B revolver consolidating three legacy facilities. With $4.9B of cash on hand and FCF margin near 2.5% in the quarter, the balance sheet is no longer the constraint it was a few years ago. The closing was vintage Hollar:Strip out the one-time refund and the narrative holds up: a large-cap distributor exiting the year with momentum, a cleaner balance sheet, and a guide that beats its own long-term target — with the honest caveat that GMPD's recovery is still hostage to oil, tariffs, and the length of a distant conflict.By any metric, whether set at either of our 2 Investor Days or our guidance updates along the way, we have done what we said we would and more.